Cover Image
市場調查報告書

睡眠呼吸中止症:開發平台分析

Sleep Apnea - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229810
出版日期 內容資訊 英文 60 Pages
訂單完成後即時交付
價格
Back to Top
睡眠呼吸中止症:開發平台分析 Sleep Apnea - Pipeline Review, H2 2016
出版日期: 2016年08月17日 內容資訊: 英文 60 Pages
簡介

睡眠呼吸中止症是潛在的嚴重睡眠障礙,造成呼吸中止又再開。症候有睡眠過度、起床時的頭痛、失眠症、起床時嘴乾及喉嚨痛等。危險因子有過度肥胖及家族病史、吸煙、氣管狹窄等。

本報告提供睡眠呼吸中止症的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊,再加上最新的新聞和發表。

簡介

  • 調查範圍

睡眠呼吸中止症 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業正在開發的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥開發企業

  • Galleon Pharmaceuticals
  • RespireRx Pharmaceuticals Inc.
  • SK Biopharmaceuticals Co., Ltd.
  • Vivus, Inc.

治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • (phentermine + topiramate) ER
  • CX-1739
  • dexloxiglumide
  • dronabinol
  • GAL-475
  • GAL-475 Backups
  • itriglumide
  • SKL-N05
  • 睡眠呼吸中止症用小分子

最近的開發平台趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8365IDB

Summary

Global Markets Direct's, 'Sleep Apnea - Pipeline Review, H2 2016', provides an overview of the Sleep Apnea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Sleep Apnea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sleep Apnea and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Sleep Apnea
  • The report reviews pipeline therapeutics for Sleep Apnea by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Sleep Apnea therapeutics and enlists all their major and minor projects
  • The report assesses Sleep Apnea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Sleep Apnea

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Sleep Apnea
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Sleep Apnea pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Sleep Apnea Overview
  • Therapeutics Development
    • Pipeline Products for Sleep Apnea - Overview
    • Pipeline Products for Sleep Apnea - Comparative Analysis
  • Sleep Apnea - Therapeutics under Development by Companies
  • Sleep Apnea - Therapeutics under Investigation by Universities/Institutes
  • Sleep Apnea - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Sleep Apnea - Products under Development by Companies
  • Sleep Apnea - Products under Investigation by Universities/Institutes
  • Sleep Apnea - Companies Involved in Therapeutics Development
    • Galleon Pharmaceuticals
    • RespireRx Pharmaceuticals Inc.
    • SK Biopharmaceuticals Co., Ltd.
    • Vivus, Inc.
  • Sleep Apnea - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (phentermine + topiramate) ER - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CX-1739 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dronabinol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GAL-475 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GAL-475 Backups - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SKL-N05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Sleep Apnea - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Sleep Apnea - Dormant Projects
  • Sleep Apnea - Discontinued Products
  • Sleep Apnea - Product Development Milestones
    • Featured News & Press Releases
      • Jun 14, 2016: Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting
      • Feb 29, 2016: RespireRx Pharmaceuticals Announces Removal of FDA Clinical Hold on CX1739 and Initiation of Phase IIA Clinical Trial by March 31, 2016
      • Jun 08, 2015: Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Clinical Development Program Evaluating JZP-110 as a Potential Treatment of EDS Associated with Narcolepsy or with OSA
      • May 14, 2015: VIVUS Announces Scientific Presentations
      • May 04, 2015: Cortex Pharmaceuticals Announces Publication of Research Results on the Use of Ampakines CX1739 in the Treatment of Respiratory Disorders
      • May 04, 2015: Cortex Pharmaceuticals Announces Publication of Research Results on the Use of Ampakines CX1739 in the Treatment of Respiratory Disorders
      • May 15, 2014: VIVUS Announces Qsymia Presentation at the American Association of Clinical Endocrinologists
      • Jul 01, 2013: VIVUS Announces Initial Availability of Qsymia Through Certified Retail Pharmacies
      • Nov 12, 2012: Study Finds Significant Improvements In Patients With Obstructive Sleep Apnea Treated With Phentermine And Topiramate Extended-Release Capsules
      • Jan 09, 2012: VIVUS Provides Update On Regulatory Status Of Qnexa
      • Nov 03, 2011: FDA Accepts New Drug Application Filing For Qnexa
      • Apr 26, 2011: Cortex Receives US Patent For Lead AMPAKINE Molecule CX1739
      • Feb 02, 2011: Cortex's Ampakine CX1739 Improves Respiratory Parameters In Obstructive Sleep Apnea Patients
      • Jan 07, 2010: VIVUS Announces Positive Results From Phase II Study Of Qnexa In Obstructive Sleep Apnea
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Sleep Apnea, H2 2016
  • Number of Products under Development for Sleep Apnea - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Sleep Apnea - Pipeline by Galleon Pharmaceuticals, H2 2016
  • Sleep Apnea - Pipeline by RespireRx Pharmaceuticals Inc., H2 2016
  • Sleep Apnea - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
  • Sleep Apnea - Pipeline by Vivus, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Sleep Apnea - Dormant Projects, H2 2016
  • Sleep Apnea - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Sleep Apnea, H2 2016
  • Number of Products under Development for Sleep Apnea - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top